Toniv,

Correct. There were very few 3-point MACE events from SUSTAIN and ASSURE Phase 2 trials, both of which were only ~6 month in duration. The requirements of BETonMACE to be in low-HDL, diabetic, recent acute coronary syndrome patients, as well as the increased length of trial (12-24 month dosing, average 18 months) will boost the 3-point MACE frequency and total.

BDAZ